91 related articles for article (PubMed ID: 18027714)
21. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo.
Müller C; Brühlmeier M; Schubiger PA; Schibli R
J Nucl Med; 2006 Dec; 47(12):2057-64. PubMed ID: 17138750
[TBL] [Abstract][Full Text] [Related]
22. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate.
Müller C; Forrer F; Schibli R; Krenning EP; de Jong M
J Nucl Med; 2008 Feb; 49(2):310-7. PubMed ID: 18199624
[TBL] [Abstract][Full Text] [Related]
23. Electrostatic binding with tat and other cationic peptides increases cell accumulation of 99mTc-antisense DNAs without entrapment.
Zhang YM; Liu CB; Liu N; Ferro Flores G; He J; Rusckowski M; Hnatowich DJ
Mol Imaging Biol; 2003; 5(4):240-7. PubMed ID: 14499139
[TBL] [Abstract][Full Text] [Related]
24. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
[TBL] [Abstract][Full Text] [Related]
25. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo.
Li GC; He F; Shao X; Urano M; Shen L; Kim D; Borrelli M; Leibel SA; Gutin PH; Ling CC
Cancer Res; 2003 Jun; 63(12):3268-74. PubMed ID: 12810658
[TBL] [Abstract][Full Text] [Related]
26. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
[TBL] [Abstract][Full Text] [Related]
27. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation.
Rossin R; Pan D; Qi K; Turner JL; Sun X; Wooley KL; Welch MJ
J Nucl Med; 2005 Jul; 46(7):1210-8. PubMed ID: 16000291
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties.
Chen J; Cheng Z; Owen NK; Hoffman TJ; Miao Y; Jurisson SS; Quinn TP
J Nucl Med; 2001 Dec; 42(12):1847-55. PubMed ID: 11752084
[TBL] [Abstract][Full Text] [Related]
29. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
30. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
31. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.
Liu G; He J; Dou S; Gupta S; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1115-23. PubMed ID: 16133391
[TBL] [Abstract][Full Text] [Related]
32. Antisense targeting in cell culture with radiolabeled DNAs--a brief review of recent progress.
Hnatowich DJ; Nakamura K
Ann Nucl Med; 2004 Jul; 18(5):363-8. PubMed ID: 15462397
[TBL] [Abstract][Full Text] [Related]
33. Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys.
Müller C; Schibli R; Forrer F; Krenning EP; de Jong M
Nucl Med Biol; 2007 Aug; 34(6):603-8. PubMed ID: 17707799
[TBL] [Abstract][Full Text] [Related]
34. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
35. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy.
Kang JH; Chung JK; Lee YJ; Shin JH; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2004 Sep; 45(9):1571-6. PubMed ID: 15347726
[TBL] [Abstract][Full Text] [Related]
36. Nonspecific cellular accumulation of 99mTc-labeled oligonucleotides in culture is influenced by their guanine content.
Wang Y; Liu X; Zhang Y; Liu G; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2007 Jan; 34(1):47-54. PubMed ID: 17210461
[TBL] [Abstract][Full Text] [Related]
37. Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment.
Yoo TM; Chang HK; Choi CW; Webber KO; Le N; Kim IS; Eckelman WC; Pastan I; Carrasquillo JA; Paik CH
J Nucl Med; 1997 Feb; 38(2):294-300. PubMed ID: 9025758
[TBL] [Abstract][Full Text] [Related]
38. [Study on the antisense inhibition effect of liposome-mediated radiolabled antisense oligonucleotides of c-myc mRNA].
Zheng J; Tan T; Pan W; Zhang C
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):413-6. PubMed ID: 12910676
[TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
Riedel F; Götte K; Hörmann K; Grandis JR
Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
[TBL] [Abstract][Full Text] [Related]
40. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
